Vericel Co. (NASDAQ:VCEL) is Kent Lake Capital LLC’s 7th Largest Position

Kent Lake Capital LLC increased its holdings in Vericel Co. (NASDAQ:VCELFree Report) by 39.5% in the 3rd quarter, Holdings Channel reports. The fund owned 300,000 shares of the biotechnology company’s stock after purchasing an additional 85,000 shares during the period. Vericel makes up about 3.9% of Kent Lake Capital LLC’s portfolio, making the stock its 7th biggest position. Kent Lake Capital LLC’s holdings in Vericel were worth $10,056,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Gamco Investors INC. ET AL lifted its stake in Vericel by 1.9% in the 2nd quarter. Gamco Investors INC. ET AL now owns 17,510 shares of the biotechnology company’s stock worth $658,000 after acquiring an additional 325 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Vericel by 8.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 344 shares in the last quarter. Arizona State Retirement System lifted its stake in Vericel by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 12,665 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 351 shares in the last quarter. LPL Financial LLC lifted its stake in Vericel by 6.6% in the 2nd quarter. LPL Financial LLC now owns 8,348 shares of the biotechnology company’s stock worth $314,000 after acquiring an additional 518 shares in the last quarter. Finally, Gotham Asset Management LLC lifted its stake in Vericel by 3.6% in the 3rd quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company’s stock worth $513,000 after acquiring an additional 538 shares in the last quarter.

Vericel Stock Up 0.1 %

Shares of VCEL stock traded up $0.06 during trading on Monday, reaching $44.77. The company had a trading volume of 394,451 shares, compared to its average volume of 634,925. The firm’s 50 day simple moving average is $41.94 and its two-hundred day simple moving average is $37.02. Vericel Co. has a one year low of $27.92 and a one year high of $50.09.

Vericel (NASDAQ:VCELGet Free Report) last released its earnings results on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.08. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The company’s revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.12 EPS. As a group, research analysts predict that Vericel Co. will post 0.11 EPS for the current year.

Insider Transactions at Vericel

In other news, Director Robert L. Md Zerbe sold 2,200 shares of Vericel stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $38.09, for a total transaction of $83,798.00. Following the sale, the director now owns 30,895 shares of the company’s stock, valued at approximately $1,176,790.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Robert L. Md Zerbe sold 2,300 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $44.22, for a total transaction of $101,706.00. Following the completion of the transaction, the director now owns 23,395 shares in the company, valued at approximately $1,034,526.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert L. Md Zerbe sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $38.09, for a total value of $83,798.00. Following the transaction, the director now owns 30,895 shares of the company’s stock, valued at approximately $1,176,790.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,426 shares of company stock valued at $1,174,397. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

VCEL has been the subject of several research analyst reports. HC Wainwright increased their price objective on Vericel from $46.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday. TheStreet raised Vericel from a “d+” rating to a “c-” rating in a research note on Monday, January 29th. Finally, Truist Financial raised their price target on Vericel from $51.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Vericel currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.40.

Get Our Latest Stock Report on VCEL

About Vericel

(Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Read More

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCELFree Report).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.